汇宇制药：全资子公司拟与同源康签署全国总代理协议

Core Insights - The company Huayu Pharmaceutical announced that its wholly-owned subsidiary Huichenxing plans to sign a national general agency agreement with Tongyuan Kang for the product "TY-9591" [1] - Tongyuan Kang has agreed to grant the national agency rights for "TY-9591" to Huichenxing, with a milestone upfront payment of 150 million RMB [1] - "TY-9591" is an orally administered, irreversible third-generation EGFR (epidermal growth factor receptor) inhibitor developed independently by Tongyuan Kang [1]